Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
T-VEC with Nivolumab and Ipilimumab in Localized Breast Cancer
NCT04185311Phase 1Terminated
- Sponsor
- UCLA Jonsson Comprehensive Cancer Center
- Start
- Jul 2019
- Primary completion
- May 2023
- Modality
- Oncolytic Viruses
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of talimogene laherparepvec in breast cancer, sponsored by UCLA Jonsson Comprehensive Cancer Center. Primary endpoint: Incidence and severity of adverse events. Started Jul 2019; status: terminated.
02
Drugs
talimogene laherparepvec
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT04185311.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04185311.